PBAC's latest decision on Sofosbuvir with velpatasvir: Noted (2017). Considered for Treatment of chronic hepatitis C virus infection (all genotypes 1, 2, 3, 4, 5 or 6).
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2016
Submissions
2
2016 → 2017
Eligible population
Adults with chronic hepatitis C virus infection of any genotype (1–6).
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
Other
Comparator
ledipasvir with sofosbuvir, paritaprevir with ritonavir with ombitasvir and dasabuvir +/- RBV, sofosbuvir in combination with RBV, daclatasvir and sofosbuvir, grazoprevir with elbasvir +/- RBV
Economic model
Not modelled
ICER note
This is a minor submission regarding interchangeability advice under Section 101(3BA); no economic evaluation was conducted.